← All insights
DSCSA · Exception management

DSCSA Exceptions: From Missing Data to Clear Resolution

Connect each discrepancy to the affected stock, an accountable owner, and evidence that supports the next action.

Hakile Life Sciences Advisors

A missing message, a quantity difference, and a failed verification request can all interrupt operations. Each needs an investigation path that identifies the affected product and the evidence required for a decision.

Identify the type of exception

Start with the observed facts. Establish the product, shipment reference, affected quantities, detection time, and original system response.

  • Missing data: Trace the message from creation through transmission and application processing.
  • Quantity or identifier differences: Compare the physical contents, warehouse records, and tracing information.
  • Verification failure: Separate a technical timeout from a negative verification result.

A duplicate electronic record and duplicate identifiers on separate packages are different concerns. Assess the evidence before choosing a correction or product investigation.

Connect the case to inventory

Assign one case owner and identify the person authorized to change inventory status. Receiving, serialization support, IT, quality, and the supplier may each contribute to the investigation.

FDA recognizes that clerical tracing discrepancies may occur without indicating suspect product. Its guidance recommends that purchasing wholesalers, dispensers, and repackagers resolve identified discrepancies within 10 business days, and that affected product not be sold to the next trading partner until the discrepancy is documented and resolved. These are guidance recommendations, not a universal statutory ticket deadline. See FDA’s enhanced security guidance, Section V.D.

If the product is determined to be suspect, follow the applicable quarantine and investigation requirements. An operational hold and a statutory suspect product investigation serve different purposes.

Use the right escalation clock

Set internal response targets based on product concerns, affected stock, and operational impact. Keep regulatory notification requirements visible to the designated compliance owner.

Manufacturers, repackagers, wholesale distributors, and dispensers must notify FDA and all appropriate immediate trading partners within 24 hours after determining product is illegitimate. FDA also has a separate notification requirement for manufacturers concerning a high risk of illegitimacy. See FDA’s notification instructions.

Confirm the correction worked

Retain the original payload, response, investigation findings, and approval. Apply the supported correction method and check the recipient’s processing result before closing the technical issue.

For wholesale distributor saleable returns, required product identifier verification must be completed before further distribution, subject to applicable exemptions. A timeout is not a completed verification. See Section 582(c)(4)(D).

Illustrative scenario: A delivery contains 12 packages, but its tracing information lists 10. The owner reconciles the physical contents with the supplier, coordinates the appropriate data correction, checks processing, and records the authorized inventory decision.

Close with evidence and review recurrence

Use a closure checklist covering affected product, successful corrections, inventory status, retained evidence, and any linked investigation or notification. Technical recovery alone does not authorize product release.

Review recurring causes alongside transaction volumes and case age. The Hakile team helps organizations investigate discrepancies, clarify ownership, and improve coordination across suppliers and connected systems.

Discuss your exception management process.

Put perspective into practice

Explore what this means for your operations.

Discuss your challenge →